Cargando…
Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212360/ http://dx.doi.org/10.1016/S0016-5085(22)62390-4 |
| _version_ | 1784730567223279616 |
|---|---|
| author | Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli bloom, Nathaniel Neill, Jennifer Le, Helen Collins, Angelina Dulai, Parambir Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Weiskopf, Daniella Chang, John T. Dan, Jennifer M. |
| author_facet | Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli bloom, Nathaniel Neill, Jennifer Le, Helen Collins, Angelina Dulai, Parambir Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Weiskopf, Daniella Chang, John T. Dan, Jennifer M. |
| author_sort | Boland, Brigid S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212360 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92123602022-06-22 Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli bloom, Nathaniel Neill, Jennifer Le, Helen Collins, Angelina Dulai, Parambir Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Weiskopf, Daniella Chang, John T. Dan, Jennifer M. Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212360/ http://dx.doi.org/10.1016/S0016-5085(22)62390-4 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli bloom, Nathaniel Neill, Jennifer Le, Helen Collins, Angelina Dulai, Parambir Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Weiskopf, Daniella Chang, John T. Dan, Jennifer M. Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES |
| title | Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES |
| title_full | Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES |
| title_fullStr | Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES |
| title_full_unstemmed | Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES |
| title_short | Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES |
| title_sort | tu1552: preserved sars-cov-2 vaccine cell-mediated immunogenicity in inflammatory bowel disease patients on immunemodulating therapies |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212360/ http://dx.doi.org/10.1016/S0016-5085(22)62390-4 |
| work_keys_str_mv | AT bolandbrigids tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT goodwinbenjamin tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT zhangzeli tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT bloomnathaniel tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT neilljennifer tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT lehelen tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT collinsangelina tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT dulaiparambir tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT singhsiddharth tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT nguyennghiah tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT grifonialba tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT weiskopfdaniella tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT changjohnt tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies AT danjenniferm tu1552preservedsarscov2vaccinecellmediatedimmunogenicityininflammatoryboweldiseasepatientsonimmunemodulatingtherapies |